SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of ...

Researchers have identified in a new study that patients suffering from chronic obstructive pulmonary disease (COPD) who ...

Chickenpox parties are a thing of the past but the virus is still circulating. Most illness is mild but some people can ...

A new study suggests that the shingles vaccine may help prevent dementia by reducing the risk of varicella-zoster virus ...

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Varicella Zoster Virus Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ...

A review of 155 scientific studies found influenza and COVID infections raised the risk of heart attack or stroke as much as ...

Vaccine exemptions overall are also on the rise. Almost 1,800 students in Allegheny County submitted medical, religious or ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

One in every nine patients tested for viral infections across India between January and June 2025 was found positive for ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil ...